Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 17/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.67 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 2/20 | 0.64 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | ITK | Q08881 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763232 | 0.95 | SYK (0.69) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL763624 | 0.92 | SYK (0.69) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL12904520 | 0.91 | EGFR (0.62) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL915061 | 0.89 | EGFR (0.67) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL29761550 | 0.89 | SYK (0.72) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL14659023 | 0.89 | SYK (0.72) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL914840 | 0.88 | EGFR (0.62) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL764204 | 0.88 | SYK (0.71) | SYKKCNH2AURKBZAP70MAPK3 | |
| SCHEMBL12904521 | 0.87 | EGFR (0.60) | SYKKCNH2AURKBZAP70EGFR | |
| SCHEMBL763221 | 0.87 | SYK (0.67) | SYKKCNH2AURKBZAP70EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | SYK 1/4885KCNH2 3335/4885AURKB 511/4885 |
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | SYK 72/4885KCNH2 3916/4885AURKB 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.